NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Descending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
65162-0843-06 | 65162-0843 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 10, 2017 | Feb. 1, 2024 | No Longer Used |
65162-0844-06 | 65162-0844 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 10, 2017 | Feb. 1, 2024 | No Longer Used |
65162-0844-16 | 65162-0844 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 10, 2017 | Feb. 1, 2024 | No Longer Used |
65162-0844-50 | 65162-0844 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 10, 2017 | Feb. 1, 2024 | No Longer Used |
65597-0402-20 | 65597-0402 | pexidartinib | Turalio | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R, KIT, FLT3 | Oral | Aug. 2, 2019 | Jan. 31, 2024 | No Longer Used |
65597-0402-28 | 65597-0402 | pexidartinib | Turalio | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R, KIT, FLT3 | Oral | Aug. 2, 2019 | Jan. 31, 2024 | No Longer Used |
65597-0504-04 | 65597-0504 | QUIZARTINIB | VANFLYTA | 17.7 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | July 20, 2023 | In Use | |
65597-0504-28 | 65597-0504 | QUIZARTINIB | VANFLYTA | 17.7 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | July 20, 2023 | In Use | |
65597-0511-04 | 65597-0511 | QUIZARTINIB | VANFLYTA | 26.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | July 20, 2023 | In Use | |
65597-0511-28 | 65597-0511 | QUIZARTINIB | VANFLYTA | 26.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | July 20, 2023 | In Use | |
65219-0359-50 | 65219-0359 | CISPLATIN | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 1, 2023 | In Use | |
68001-0422-37 | 68001-0422 | Decitabine | Decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Oct. 21, 2019 | In Use | |
68001-0504-54 | 68001-0504 | Azacitidine | Azacitidine | 100.0 mg/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | June 11, 2021 | In Use | |
68001-0266-27 | 68001-0266 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 16, 2014 | In Use | |
68001-0266-30 | 68001-0266 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 15, 2014 | In Use | |
68001-0266-31 | 68001-0266 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 15, 2014 | In Use | |
68001-0266-32 | 68001-0266 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 16, 2014 | In Use | |
68180-0738-01 | 68180-0738 | decitabine | decitabine | 50.0 mg/20mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 6, 2019 | Jan. 1, 2040 | In Use |
70860-0206-50 | 70860-0206 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 12, 2017 | In Use | |
70860-0206-51 | 70860-0206 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct. 16, 2017 | In Use | |
31722-0362-31 | 31722-0362 | MELPHALAN HYDROCHLORIDE | MELPHALAN HYDROCHLORIDE | 50.0 mg/10ml | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | May 23, 2024 | In Use | |
71288-0165-53 | 71288-0165 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 10, 2023 | Jan. 2, 2025 | In Use |
71288-0165-54 | 71288-0165 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 10, 2023 | In Use | |
75907-0095-40 | 75907-0095 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | April 15, 2024 | In Use | |
83831-0111-01 | 83831-0111 | Pemetrexed dipotassium | PEMETREXED DIPOTASSIUM | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | June 28, 2024 | In Use |
Found 10,000 results in 9 milliseconds — Export these results